Jefferies John

CMO John Jefferies buys 5,941 shares for $0.00 at Daxor; holdings rise to 23,557 shares (+33.7%) during -26.0% 90-day decline

Chief Medical Officer John Jefferies executed 2 separate purchases totaling 5,941 shares for $0.00 on 2026-03-20, increasing his stake by 33.7% to 23,557 shares. The zero transaction cost suggests these shares were acquired through equity compensation (vesting, grant, or exercise), not discretionary open-market buying. This acquisition occurred while Daxor's stock has declined 26.0% over 90 days and trades 30.6% below its 52-week high of $14.75, currently at $10.23. The company remains unprofitable with a net loss of $-4,183,669.00 in its latest full fiscal year and posted declining annual revenue growth of -8.4%, making the timing context—though forced by non-volitional equity compensation—relevant to assessing insider confidence given the company's financial deterioration.

CMO John Jefferies purchases 2,344 shares of DAXOR (DXR); holdings rise 15.3% to 17.6K shares.

Jefferies John, Chief Medical Officer, purchased 2,344 shares on 2025-11-12, increasing his holdings by 15.3% to 17,616 shares total. The transaction occurred when the stock trades at $13.00, down 7.1% from its 52-week high of $14.00 but up 22.6% over the past 90 days. This purchase occurs against a backdrop of material operational headwinds: the company reported net income of $-4,183,669.00 for the latest full fiscal year, annual revenue declined 8.4% year-over-year, and most recent quarter revenue was only $340,907.00 on a $54.6M market cap. The timing of the buy (after a 22.6% three-month rally but below recent peaks) and the absolute increase in position size warrant examination of whether this reflects opportunistic accumulation or a scheduled plan, particularly given the company's sustained unprofitability and shrinking revenues.